Showing 1 - 10 of 10
This paper provides insights into the determinants of bargaining power and how they affect drug prices. Our data show that drug prices vary across buyers and time periods. We estimate a structural bargaining model where drug suppliers and buyers engage in bilateral bargaining over drug prices....
Persistent link: https://www.econbiz.de/10012138768
This paper provides insights into the determinants of bargaining power and how they affect drug prices. Our data show that drug prices vary across buyers and time periods. We estimate a structural bargaining model where drug suppliers and buyers engage in bilateral bargaining over drug prices....
Persistent link: https://www.econbiz.de/10012845687
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10010229875
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D investments...
Persistent link: https://www.econbiz.de/10012833741
In the last ten years, the pharmaceutical industry has experienced steep, unprecedented price increases. Pharmaceutical companies engage in R&D cooperations to cope with rocketing research and development (R&D) expenses.We study the impact of R&D cooperations on firms' research activities and...
Persistent link: https://www.econbiz.de/10012951300
Persistent link: https://www.econbiz.de/10010206973
Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...
Persistent link: https://www.econbiz.de/10013315639
Persistent link: https://www.econbiz.de/10011702980
Pharmaceutical firms spend increasing amounts in mergers and acquisitions (M&As), which raises the question of whether sufficient investment is left after mergers to further develop firms' internal drug development capability. We evaluate the effects of M&As on firms' post-merger R&D...
Persistent link: https://www.econbiz.de/10012219372
In the pharmaceutical industry, firms frequently engage in licensing agreements to overcome innovation challenges and keep up with the pace of developing new drugs. Licensing helps firms jointly develop new drugs and acquire external knowledge, which helps improve their internal drug...
Persistent link: https://www.econbiz.de/10012219514